Allarity Therapeutics and FivepHusion have entered into a collaborative agreement to support clinical development of Deflexifol™ with DRP® Companion Diagnostics.
As part of the newly established partnership, Allarity Therapeutics and FivepHusion are collaborating to advance the clinical development of Deflexifol™ for the treatment of solid tumours. Under this agreement, Allarity will provide support by leveraging its drug-specific DRP® companion diagnostics, such as the validated DRP®-5FU companion diagnostic.
This collaboration aims to incorporate DRP® into the upcoming phase 1b/2a trial of their promising drug, Deflexifol™, in treating 1st line unresectable metastatic colourectal cancer. The combined efforts of these two leading entities have the potential to revolutionise the field of precision medicine by offering oncologists an advanced companion diagnostic tool.
The strategic collaboration between Allarity Therapeutics and FivepHusion advances true personalised cancer care by harnessing the power of the DRP® companion diagnostic technology. This joint effort aims to identify patients who are most likely to benefit from Deflexifol™, a promising therapeutic candidate for various cancer types.
